Clémence Guiraut
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clémence Guiraut has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Guillaume Sébire
Department of Pediatrics, McGill University, Research Institute of the McGill University Health Centre Montreal, QC, Canada
3 shared publications - Mathilde Chevin
Department of Pediatrics, McGill University, Research Institute of the McGill University Health Centre Montreal, QC, Canada
2 shared publications - Caroline Maurice‐Gelinas
Département de Pharmacologie‐physiologie Université de Sherbrooke 3001‐ 12e avenue Nord Sherbrooke Quebec J1H 5N4 Canada
1 shared publication - Cathy Vaillancourt
Centre de Recherche Interuniversitaire en Reproduction et Développement-Réseau Québécois en Reproduction (CIRD-RQR), Université de Montréal, St-Hyacinthe, QC J2S 2M2, Canada
1 shared publication - Djordje Grbic
Département de pédiatrie, Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Québec, J1H 5N4, Canada
1 shared publication - Jessica Deslauriers
Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Centre, Québec, QC G1V 4G2, Canada; Faculty of Pharmacy, Université Laval, Québec, QC G1V 0A6, Canada
1 shared publication
Latest Publications
- Open Access
- 30 July 2018
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 214
Effect of hypothermia on interleukin-1 receptor antagonist pharmacodynamics in inflammatory-sensitized hypoxic-ischemic encephalopathy of term newborns
Hypothermia is increasingly tested in several neurological conditions, such as neonatal encephalopathy, stroke, traumatic brain injury, subarachnoid hemorrhage, spinal cord injury, and neurological outcomes of cardiac arrest. Current studies aim to increase benefits of hypothermia with new add-on therapies including immunomodulatory agents. Hypothermia has been shown to affect the metabolism of commonly used drugs, including those acting on neuroimmune pathways. This study focuses on the effect of hypothermia on interleukin-1 receptor antagonist pharmacodynamics in a model of neonatal encephalopathy. The effect of hypothermia on (i) the tissue concentration of the interleukin-1 receptor antagonist, (ii) the interleukin-1 inflammatory cascade, and (iii) the neuroprotective potential of interleukin-1 receptor antagonist has been assessed on our rat model of neonatal encephalopathy resulting from inflammation induced by bacterial compound plus hypoxia-ischemia. Hypothermia reduced the surface of core and penumbra lesions, as well as alleviated the brain weight loss induced by LPS+HI exposure. Hypothermia compared to normothermia significantly increased (range 50–65%) the concentration of the interleukin-1 receptor antagonist within the central nervous system. Despite this increase of intracerebral interleukin-1 receptor antagonist concentration, the intracerebral interleukin-1-induced tumor necrosis factor-alpha cascade was upregulated. In hypothermic condition, the known neuroprotective effect of interleukin-1 receptor antagonist was neutralized (50 mg/kg/12 h for 72 h) or even reversed (200 mg/kg/12 h for 72 h) as compared to normothermic condition. Hypothermia interferes with the pharmacodynamic parameters of the interleukin-1 receptor antagonist, through a bioaccumulation of the drug within the central nervous system and a paradoxical upregulation of the interleukin-1 pathway. These effects seem to be at the origin of the loss of efficiency or even toxicity of the interleukin-1 receptor antagonist when combined with hypothermia. Such bioaccumulation could happen similarly with the use of other drugs combined to hypothermia in a clinical context.
- 30 July 2018
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 214
Open AccessEffect of hypothermia on interleukin-1 receptor antagonist pharmacodynamics in inflammatory-sensitized hypoxic-ischemic encephalopathy of term newborns
Hypothermia is increasingly tested in several neurological conditions, such as neonatal encephalopathy, stroke, traumatic brain injury, subarachnoid hemorrhage, spinal cord injury, and neurological outcomes of cardiac arrest. Current studies aim to increase benefits of hypothermia with new add-on therapies including immunomodulatory agents. Hypothermia has been shown to affect the metabolism of commonly used drugs, including those acting on neuroimmune pathways. This study focuses on the effect of hypothermia on interleukin-1 receptor antagonist pharmacodynamics in a model of neonatal encephalopathy. The effect of hypothermia on (i) the tissue concentration of the interleukin-1 receptor antagonist, (ii) the interleukin-1 inflammatory cascade, and (iii) the neuroprotective potential of interleukin-1 receptor antagonist has been assessed on our rat model of neonatal encephalopathy resulting from inflammation induced by bacterial compound plus hypoxia-ischemia. Hypothermia reduced the surface of core and penumbra lesions, as well as alleviated the brain weight loss induced by LPS+HI exposure. Hypothermia compared to normothermia significantly increased (range 50–65%) the concentration of the interleukin-1 receptor antagonist within the central nervous system. Despite this increase of intracerebral interleukin-1 receptor antagonist concentration, the intracerebral interleukin-1-induced tumor necrosis factor-alpha cascade was upregulated. In hypothermic condition, the known neuroprotective effect of interleukin-1 receptor antagonist was neutralized (50 mg/kg/12 h for 72 h) or even reversed (200 mg/kg/12 h for 72 h) as compared to normothermic condition. Hypothermia interferes with the pharmacodynamic parameters of the interleukin-1 receptor antagonist, through a bioaccumulation of the drug within the central nervous system and a paradoxical upregulation of the interleukin-1 pathway. These effects seem to be at the origin of the loss of efficiency or even toxicity of the interleukin-1 receptor antagonist when combined with hypothermia. Such bioaccumulation could happen similarly with the use of other drugs combined to hypothermia in a clinical context.
- 9 September 2016
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 55 (1) , 1-8
Neuroprotective effects of hypothermia in inflammatory‐sensitized hypoxic‐ischemic encephalopathy
Background: Despite the recent introduction of hypothermia as a mandatory standard of care, the incidence of neonatal encephalopathy in full‐term newborns and its devastating neuro‐behavioral outcomes continues to be a major individual, familial and social issue. Neonatal encephalopathy is mainly due to the compounding and interacting effects of hypoxia‐ischemia and inflammation resulting from placental and other perinatal infections. It is unclear why hypothermia is effective in alleviating neonatal encephalopathy in some, but not all, full‐term newborns. However, newborns exposed to inflammatory‐sensitized hypoxia‐ischemia seem to have less therapeutic benefit from hypothermia than those exposed to hypoxia‐ischemia alone.Objectives: To clarify this uncertainty, we tested the efficacy of hypothermia in a double‐hit model of neonatal encephalopathy induced by inflammatory‐sensitized hypoxia‐ischemia.Methods: Using a rat preclinical model of endotoxin plus hypoxia‐ischemia‐induced neonatal encephalopathy of term newborns, we assessed the following in pups exposed (or not) to hypothermia: the extent of brain injuries and the expressions of molecules implicated in neural cell death, namely: pro‐inflammatory cytokines, matrix metalloproteinase‐9, antioxidant enzymes, as well as receptor‐interacting protein‐3.Results: Hypothermia was neuroprotective on inflammatory‐sensitized hypoxia‐ischemia‐induced penumbra, but not core, brain injuries. This beneficial effect was associated with a hypothermia‐induced increase of antioxidant enzymes (superoxide dismutase‐1, glutathione peroxidase‐1), but was not associated with any variations of the other inflammatory mediators tested, namely: interleukin‐1β, interleukin‐1 receptor antagonist, tumor necrosis factor‐α and matrix metalloproteinase‐9.Conclusion: Hypothermia is neuroprotective against inflammatory‐sensitized hypoxia‐ischemia possibly through a hypothermia‐induced increase of antioxidant enzymes. This neuroprotective effect seems to be independent of the interleukin‐1 system.
- 9 September 2016
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 55 (1) , 1-8
Neuroprotective effects of hypothermia in inflammatory‐sensitized hypoxic‐ischemic encephalopathy
Background: Despite the recent introduction of hypothermia as a mandatory standard of care, the incidence of neonatal encephalopathy in full‐term newborns and its devastating neuro‐behavioral outcomes continues to be a major individual, familial and social issue. Neonatal encephalopathy is mainly due to the compounding and interacting effects of hypoxia‐ischemia and inflammation resulting from placental and other perinatal infections. It is unclear why hypothermia is effective in alleviating neonatal encephalopathy in some, but not all, full‐term newborns. However, newborns exposed to inflammatory‐sensitized hypoxia‐ischemia seem to have less therapeutic benefit from hypothermia than those exposed to hypoxia‐ischemia alone.Objectives: To clarify this uncertainty, we tested the efficacy of hypothermia in a double‐hit model of neonatal encephalopathy induced by inflammatory‐sensitized hypoxia‐ischemia.Methods: Using a rat preclinical model of endotoxin plus hypoxia‐ischemia‐induced neonatal encephalopathy of term newborns, we assessed the following in pups exposed (or not) to hypothermia: the extent of brain injuries and the expressions of molecules implicated in neural cell death, namely: pro‐inflammatory cytokines, matrix metalloproteinase‐9, antioxidant enzymes, as well as receptor‐interacting protein‐3.Results: Hypothermia was neuroprotective on inflammatory‐sensitized hypoxia‐ischemia‐induced penumbra, but not core, brain injuries. This beneficial effect was associated with a hypothermia‐induced increase of antioxidant enzymes (superoxide dismutase‐1, glutathione peroxidase‐1), but was not associated with any variations of the other inflammatory mediators tested, namely: interleukin‐1β, interleukin‐1 receptor antagonist, tumor necrosis factor‐α and matrix metalloproteinase‐9.Conclusion: Hypothermia is neuroprotective against inflammatory‐sensitized hypoxia‐ischemia possibly through a hypothermia‐induced increase of antioxidant enzymes. This neuroprotective effect seems to be independent of the interleukin‐1 system.